Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
NEWARK, Calif., Feb. 08, 2016 -- Depomed, Inc. (NASDAQ:DEPO) announced today a favorable Markman claim construction ruling by Judge Claire Cecchi of the United States District Court for the District of New Jersey has been issued in the ongoing patent infringement case against the three filers of Abbreviated New Drug Applications (ANDA) with Depomed prevailing on all disputed claims. These filers are seeking to market generic versions of Nucynta® (tapentadol) and Nucynta® ER (tapentadol) extended released tablets.
In a Markman ruling, also known as a Claim Construction Ruling, the court determines the meaning of disputed patent terms at issue in patent litigation. Judge Cecchi construed all disputed patent terms as proposed by plaintiffs Depomed and its licensor Grünenthal GmbH.
About Depomed
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com.
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995. The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to, those related to the ongoing ANDA litigation related to Nucynta® and Nucytna® ER, uncertainties relating to enforcement of intellectual property rights in the pharmaceutical industry and other risks detailed in the company’s Securities and Exchange Commission filings, including the company’s Annual Report on Form 10-K for the year ended December 31, 2014 and most recent Quarterly Report on Form 10-Q. The inclusion of forward-looking statements should not be regarded as a representation that any of the company’s plans or objectives will be achieved. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
INVESTOR AND MEDIA CONTACT: Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000 [email protected]
